Stocksigma LogoStocksigma Logo

Alembic Pharmaceuticals Reports Robust Q2 FY27 Results with 81% PAT Growth

Alembic Pharmaceuticals delivered strong Q2 FY27 performance, with revenue growing 36% YoY to ₹26.03 bn, driven by double-digit expansion across all

Alembic Pharmaceuticals Reports Robust Q2 FY27 Results with 81% PAT Growth

Alembic Pharmaceuticals Ltd · Investor Presentation · 04 Nov 2026, 8:08 pm

Alembic Pharmaceuticals Reports Robust Q2 FY27 Results with 81% PAT Growth Alembic Pharmaceuticals delivered strong Q2 FY27 performance, with revenue growing 36% YoY to ₹26.03 bn, driven by double-digit expansion across all segments: US formulations surged 77% YoY to ₹10.03 bn, API grew 39% to ₹4.36 bn, India branded rose 14% to ₹7.25 bn, and Ex-US climbed 12% to ₹4.40 bn. EBITDA surged 78% YoY to ₹5.78 bn as EBITDA margins expanded 520 bps to 22%, while PAT attributable to shareholders jumped 81% YoY to ₹3.35 bn. R&D spend stood at 8% of revenue.

Original exchange filing (PDF)

More announcements from Alembic Pharmaceuticals Ltd

All Alembic Pharmaceuticals Ltd announcements